Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced positive data from its ...
The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication that targets specific brain receptors without affecting dopamine pathways.